Clinical Trial News and Research

RSS

Protox reports net and comprehensive loss of $2.2 million for first quarter 2011

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today announced financial results and achievements for the quarter ended March 31, 2011.

2 Jun 2011

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

OncoSec Medical Incorporated, which is developing its advanced-stage ElectroOncology therapies to treat solid tumor cancers, announced today that one of its clinical trial advisers will present results from an ElectroImmunotherapy clinical trial for melanoma at the 2011 American Society of Clinical Oncology Annual Meeting to be held June 4-8 at McCormick Place, Chicago, IL.

2 Jun 2011

Cyberonics net sales increase 14% to $190.5 million for fiscal 2011

Cyberonics, Inc., a global leader in epilepsy management, today announced results for the fourth quarter and fiscal year ended April 29, 2011.

2 Jun 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO Pharmaceuticals, Inc. today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib in Asian subjects with non-small cell lung cancer.

2 Jun 2011

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

Symphogen announced today that Phase 2 data will be presented from an open-label, multi-center clinical trial evaluating the safety and tolerability of rozrolimupab in adult, RhD positive, non-splenectomized patients with Immune thrombocytopenia (ITP) at the 16th Congress of the European Hematology Association meeting in London, UK on June 10 from 5:45 to 7:00 PM.

2 Jun 2011

Repligen announces completion of RG1068 pre-New Drug Application meeting with U.S. FDA

Repligen Corporation today announced that the Company has concluded a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration related to its lead product candidate, RG1068 for improvement of magnetic resonance imaging of the pancreas.

2 Jun 2011

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Nuvilex, Inc. announces the favorable results of a completed Phase II clinical trial carried out in Europe against pancreatic cancer. The treatment technology used in this trial was recently acquired by Nuvilex.

2 Jun 2011

Researchers discover overactive genes that drive triple-negative breast cancer cells

Scientists at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors, a typically aggressive cancer that is highly resistant to current therapies.

2 Jun 2011

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

On May 29, 2011 XTL has announced that its rHuEPO drug which is currently in preparations for phase 2 clinical trial, has been granted an Orphan-drug designation by the US Food and Drug Administration (FDA) for treatment of Multiple Myeloma blood cancer.

2 Jun 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Adaptimmune announced that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy.

1 Jun 2011

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

Medications are the mainstay of treatment for epilepsy, but for a considerable number of patients — estimated to be as many as 1 million in the U.S. — drugs don't work. These patients suffer from a type of epilepsy known as refractory or drug-resistant epilepsy, in which drugs can't control their seizures.

1 Jun 2011

New genetic test can predict clinical outcomes in glioblastoma patients

New research proves that a change in a particular gene can identify which patients with a specific kind of brain cancer will respond better to treatment. Testing for the gene can distinguish patients with a more- or less-aggressive form of glioblastoma, the most common and an often-fatal type of primary brain cancer, and help guide therapy, the researchers say.

1 Jun 2011

Lymphoma vaccine extends disease-free survival by 14 months

A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology.

1 Jun 2011

Patrick K. Donnelly announces official launch of Aptiv Solutions

Chairman and CEO Patrick K. Donnelly today announced the official launch of Aptiv Solutions, a global biopharmaceutical and medical device development services company.

1 Jun 2011

CrystalGenomics begins enrollment in CG100649 Phase 2b osteoarthritis study

CrystalGenomics, Inc. and CG Pharmaceuticals, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced that the first patient has been enrolled for a Phase 2b clinical study of CG100649, CrystalGenomics' clinical stage novel NSAID candidate, in patients with knee or hip osteoarthritis.

1 Jun 2011

Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease

After years of building hope for a treatment, Rochester researchers and clinicians will begin the first controlled clinical trial for Juvenile Batten disease this summer, thanks to $1 million in grants from the Food and Drug Administration and the Batten Disease Support and Research Association.

1 Jun 2011

Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis

Ampio Pharmaceuticals, Inc. announced today that it received ethics board approval for a Phase 1B clinical trial in Australia of its biologic anti-inflammatory agent, Ampion.

1 Jun 2011

Radiant to expand consumer products testing capabilities

Radiant Research, Inc. today announced that it is expanding its consumer products testing capabilities through creation of a new division of Radiant Research devoted to consumer trial conduct.

31 May 2011

EpiCept completes $10.6 million 11.5% senior secured term loan facility with MidCap Financial

EpiCept Corporation today announced that it has completed a $10.6 million 11.5% senior secured term loan facility with MidCap Financial LLC.

31 May 2011

Positive results from DavosLife Natural e3 phase I clinical trial in resectable pancreatic cancer

Davos Life Science has today announced preliminary results of a phase I clinical trial of its Natural e3 delta-tocotrienol (Natural e3) in patients with resectable pancreatic cancer. Tocotrienols are highly potent members of the Vitamin E family that have been found by researchers to inhibit the growth and survival of various types of cancer cells.

30 May 2011

Clinical Trial News and Research

Protox reports net and comprehensive loss of $2.2 million for first quarter 2011

OncoSec Medical to present results of ElectroImmunotherapy clinical trial in melanoma at ASCO 2011

Cyberonics net sales increase 14% to $190.5 million for fiscal 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

Repligen announces completion of RG1068 pre-New Drug Application meeting with U.S. FDA

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Researchers discover overactive genes that drive triple-negative breast cancer cells

XTL receives FDA Orphan-drug designation for rHuEPO drug to treat Multiple Myeloma

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Non-invasive trigeminal nerve stimulation shows promise for drug-resistant epilepsy

New genetic test can predict clinical outcomes in glioblastoma patients

Lymphoma vaccine extends disease-free survival by 14 months

Patrick K. Donnelly announces official launch of Aptiv Solutions

CrystalGenomics begins enrollment in CG100649 Phase 2b osteoarthritis study

Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease

Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis

Radiant to expand consumer products testing capabilities

EpiCept completes $10.6 million 11.5% senior secured term loan facility with MidCap Financial

Positive results from DavosLife Natural e3 phase I clinical trial in resectable pancreatic cancer

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News